PNC-27, a short, laboratory-made chain of amino acids, is promoted as a cancer treatment; its designers report it kills cancer cells by opening holes in their outer membrane while sparing normal cells. The claim rests only on cells grown in the laboratory and on mice, with no human dose or registered trial. Even for early adopters, hazards are better documented than benefits: sold product was found contaminated with bacteria. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Lactate dehydrogenase (LDH) | 140–280 U/L | Index of cell rupture |
| Absolute neutrophil count | 1,500–8,000 cells/µL | Marrow suppression, infection risk |
| C-reactive protein (CRP) | <5 mg/L | Flags infection from contaminated product |
| Alanine aminotransferase (ALT) | 7–40 U/L | Liver injury |
| Serum creatinine with eGFR | 0.6–1.3 mg/dL | Kidney injury |
Cadence: No monitoring protocol has been established; if exposure had occurred: baseline before any further exposure, every 1 to 2 weeks while exposure continued, then at 4 weeks and 3 months after it stopped; same-day blood cultures for any fever.